New drug combo shows promise against Hard-to-Treat hepatitis c

NCT ID NCT00630058

Completed Disease control Sponsor: Tanabe Pharma Corporation Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-phase trial tested a new hepatitis C drug called telaprevir (MP-424) combined with two standard medications (peginterferon and ribavirin) in 20 people with genotype 1b hepatitis C. The main goals were to check safety and how the drug moves through the body. Researchers also measured how well the combo lowered virus levels. The study was completed and helped guide later, larger trials.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Telaprevir (MP-424) plus peginterferon alfa-2b and ribavirin
What this could lead to: If successful, this could point toward a more effective treatment for hepatitis C genotype 1b, potentially leading to higher cure rates.
What could go wrong: This was a very early phase 1 study with only 20 participants, so results may not apply to everyone. The combination also carries known side effects like fatigue and anemia.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEPATITIS C are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chronic hepatitis C virus infection hepatitis C virus infection

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEPATITIS C

Contacts and locations

Locations

Toranomon Hospital

Kawasaki, Takatsu-ku, Japan

More trials for these conditions

Other studies related to the condition(s) this trial covers.